A Single-arm, Open-Label, Multicenter Phase II Clinical Study to Evaluate Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Pimurutamab (Primary)
- Indications Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Shanghai Henlius Biotech
Most Recent Events
- 05 Dec 2023 According to a Henlius Biopharmaceuticals media release, results from this study were presented at the European Society for Medical Oncology Asia (ESMO Asia) Congress 2023.
- 05 Dec 2023 Results ( N=31, Cut of 2 July 2023) presented in a Henlius Biopharmaceuticals media release.
- 09 Jun 2022 Planned initiation date changed from 19 May 2022 to 19 Jun 2022.